SCHEMBL8782823

SCHEMBL8782823

CCCCOc1ccc(/C=C/C(=O)OC)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.62
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
TYR P14679 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58
SAE1 Q9UBE0 1/20 0.57
UBA2 Q9UBT2 1/20 0.57
AHR P35869 1/20 0.55
FDPS P14324 1/20 0.54
HDAC10 Q969S8 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC11 Q96DB2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142092 1.00 ABCG2 (0.62) ABCG2CA12CA1CA2TYR
SCHEMBL10389592 0.97 ABCG2 (0.59) ABCG2CA12CA1CA2TYR
SCHEMBL3489100 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL22439080 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL22439078 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL10334836 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL10334835 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL9062933 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL3489098 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR
SCHEMBL9062932 0.96 ABCG2 (0.58) ABCG2CA12CA1CA2TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139366-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2023-05-04 US disclosed
US-20210177965-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2021-06-17 US disclosed
CN-106795327-B Resin composition and optical compensation film using the same 东曹株式会社 2019-08-30 CN disclosed
CN-106795327-A Resin composition and optical compensation film using the same 东曹株式会社 2017-05-31 CN disclosed
US-8963128-B2 Compound for organic thin film transistor and organic thin film transistor using the same IDEMITSU KOSAN CO., LTD. (JP) 2015-02-24 US disclosed
US-8963128-B2 Compound for organic thin film transistor and organic thin film transistor using the same IDEMITSU KOSAN CO., LTD. (JP) 2015-02-24 US disclosed
US-20130341573-A1 PHOTOREFRACTIVE COMPOSITION COMPRISING ELECTROLYTES IN A PHOTOREFRACTIVE LAYER AND METHOD OF MAKING THEREOF NITTO DENKO CORPORATION (JP) 2013-12-26 US disclosed
US-20130341574-A1 PHOTOREFRACTIVE COMPOSITION AND DEVICE COMPRISING THE COMPOSITION NITTO DENKO CORPORATION (JP) 2013-12-26 US disclosed
WO-2013075050-A1 PHOTOREFRACTIVE DEVICE CONTAINING CARBON NANOTUBE-DOPED POLYMER LAYERS AND ITS MANUFACTURING METHOD NITTO DENKO CORPORATION (JP) 2013-05-23 WO disclosed
WO-2012116071-A1 PHOTOREFRACTIVE COMPOSITION COMPRISING ELECTROLYTES IN A PHOTOREFRACTIVE LAYER AND METHOD OF MAKING THEREOF NITTO DENKO CORPORATION (JP) 2012-08-30 WO disclosed
US-20110180790-A1 COMPOUND FOR ORGANIC THIN FILM TRANSISTOR AND ORGANIC THIN FILM TRANSISTOR USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2011-07-28 US disclosed
US-20110180790-A1 COMPOUND FOR ORGANIC THIN FILM TRANSISTOR AND ORGANIC THIN FILM TRANSISTOR USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2011-07-28 US disclosed
EP-0595995-B1 ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1997-01-15 EP disclosed
US-5514702-A Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity ABBOTT LABORATORIES (US) 1996-05-07 US disclosed
EP-0588785-A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-03-30 EP disclosed
US-5214204-A Inhibitors of biosynthesis of leukotrienes ABBOTT LABORATORIES (US) 1993-05-25 US disclosed
US-5185363-A Administering for treatment of inflammatory diseases ABBOTT LABORATORIES (US) 1993-02-09 US disclosed
EP-0588785-A4 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1991-12-30 EP disclosed
WO-1990012008-A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1990-10-18 WO disclosed
EP-0292699-A2 Urea based lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1988-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139366-A1 BRARTEMICIN ANALOGUES RXFP1, RXFP2, RXFP4 ABCG2 4866/4885CA12 2046/4885CA1 1872/4885
US-20210177965-A1 BRARTEMICIN ANALOGUES RXFP1, RXFP2, CMKLR1 ABCG2 4869/4885CA12 2123/4885CA1 1933/4885
US-20110180790-A1 COMPOUND FOR ORGANIC THIN FILM TRANSISTOR AND ORGANIC THIN FILM TRANSISTOR USING THE SAME TCF4, CDH1, RCOR1 ABCG2 356/4885CA12 3396/4885CA1 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.